Preface
Time to get real: critical and imperative change required in evidence evaluation
Journal of Thoracic Disease
2016;
8
(Suppl 5)
:S431-S434
.
(10 July 2016)
Meeting Highlights
2016 Respiratory Effectiveness Group Annual Summit Report—impact & influence of real-world respiratory evidence
Journal of Thoracic Disease
2016;
8
(Suppl 5)
:S435-S444
.
(10 July 2016)
Highlights
The role of primary care databases in developing asthma and allergy service delivery
Journal of Thoracic Disease
2016;
8
(Suppl 5)
:S445
.
(10 July 2016)
Leveraging datasets and insisting on quality to address unmet research needs—the epidemiologists’ dream
Journal of Thoracic Disease
2016;
8
(Suppl 5)
:S446
.
(10 July 2016)
Routine primary care data—the new crystal ball?
Journal of Thoracic Disease
2016;
8
(Suppl 5)
:S447
.
(10 July 2016)
Abstracts
AB020. To produce a white paper on: ‘how to develop the perfect real-time, real-world effectiveness and cost-effectiveness trial’
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB033. Assessing the appropriateness of pharmacological prescriptions for COPD to clinical guidelines: EPOCONSUL study
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB014. Effect of beta-blockers on the risk of COPD exacerbations
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB027. Long-acting beta-agonist in combination or separate inhaler as step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB040. Determinants of increase FeNO in individuals with suspected asthma
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB021. Validation of real-world, non-research thoracic CT scans for quantitative analysis of COPD
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB034. Comparative effectiveness of prescribing similar versus dissimilar inhalers for COPD therapy
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB015. Current diagnostic approaches in ILD: ILD vs. non-specialty clinics
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB028. Use of β-blockers and the risk of asthma exacerbations
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB041. Effectiveness and cost impact evaluation of fluticasone propionate/formoterol compared to fluticasone propionate/salmeterol
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB022. Validity of the five-level new version of the EQ-5D in asthma patients
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB035. Use of antibiotics among patients hospitalized for exacerbations of asthma
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB016. Characteristics of newly diagnosed COPD patients without maintenance treatment: a population-based study
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB029. Clinical utility of a molecular diagnostic in evaluation of interstitial lung disease
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB042. Allergy Working Group Update: the burden and management of rhinitis and rhinosinusitis in UK primary care
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB023. Validity of the EQ-5D-Youth in asthmatic children
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB036. Real-life experience of COPD patients on ease and accuracy of inhaler use: the REAL survey
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB017. Interstitial lung disease patient diagnostic journey (intensity)
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB030. Prevalence and incidence of bronchiectasis in Catalonia in 2012
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB024. Influences of socio-economic status on costs of asthma under universal health coverage
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB037. Drug-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB018. Improving the management of patients’ assigned COPD treatment (IMPACT): turning risk assessment into practice
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB031. Validation of claims approach to identify asthma and COPD overlap syndrome patients in the United States
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB012. Current burden of uncontrolled asthma in the general population: the OPCRD asthma state of the Union study
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB025. Medication adherence: placing the ‘when’ and ‘which’ in the equation
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB038. Pragmatic trial comparing continuing Seretide® MDI with changing to Flutiform® in asthma
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB019. Longitudinal asthma management profiles: visualisation of patient histories using multiple data sources
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB032. Opportunities for real-life respiratory research in Korea: the HIRA database and beyond
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB013. Inappropriate asthma therapy: a tale of two countries
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB026. Excess medical cost in patients with asthma and the role of comorbidity
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
AB039. Pragmatic trial stepping down Flutiform® in patients maintained on high dose ICS
Journal of Thoracic Disease
2016;
8
(Suppl 5)
.
(10 July 2016)
Disclosure:
The supplement “Impact and Influence of Real-Life Respiratory Research - Abstracts from the Respiratory Effectiveness Group 2016 Summit” was commissioned by the Editorial office, Journal of Thoracic Disease without any sponsorship or funding. David B. Price served as the unpaid Guest Editor for the supplement.
